Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

RASSURE - Virtual Reality to Soothe, Secure, Simulate Uses, and Successfully Complete the Examination (RASSURE)

17. november 2026 opdateret af: Pôle Saint Hélier

Pilot Study Evaluating the Impact of Immersive Virtual Reality-Based Habituation to Medical Care Compared With Traditional Habituation to Medical Care on Anxiety Levels in People With Disabilities Receiving Care in a Dedicated Disability Consultation Setting

The RASSURE study aims to evaluate the effect of a preparation for care programme combining a traditional habituation method with a digital immersive virtual reality tool ('PREPASOINS_VR'), compared with traditional habituation alone. In particular, the study aims to measure the impact of the use of IVR on the anxiety experienced during the actual treatment, as well as on various indicators relating to the delivery of the treatment, its progress and the experience of the patients.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

9 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults:

    • Adults (age ≥ 18) at the time of enrollment
    • Users of the Handi Accès 35 program who have experienced treatment failure in mainstream healthcare settings
    • Individuals with a psychological or mental disability (e.g., autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down syndrome, cerebral palsy, etc.) that creates significant barriers to accessing care (e.g., failure to receive care, failure due to past experience (perceived/contact-related), refusal of care, architectural barriers, anticipated failure, lack of external care options) documented in the medical record
    • Requiring a period of adjustment to care
    • Having given free and informed consent
    • Able to understand the French language (care acclimatization kits-available only in French)
    • Enrolled in a social security program or eligible for an equivalent benefit

Minors:

  • Children aged between 9 and 17 (inclusive) at the time of inclusion
  • Users of the Handi Accès 35 scheme who have been unable to access care in mainstream settings
  • People with a psychological or mental disability (for example: autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down's syndrome, cerebral palsy, etc.) which creates significant barriers to accessing care (e.g. failure to access care, failure due to experience (perception/interaction), refusal of treatment, architectural barriers, anticipated failure, no external care provision) documented in the medical record
  • Requiring a period of adjustment to care
  • Registered with a social security scheme or entitled to an equivalent benefit
  • Able to understand French (care familiarisation kits - available in French only)
  • Minors for whom free, informed and written consent has been obtained from both holders of parental authority or, in exceptional cases, from a single holder under the conditions set out in Article L1122-2 of the Public Health Code.

Caregivers:

  • Adult: a person aged 18 or over
  • Informed consent: voluntary agreement to participate in the study following a full explanation of its terms.
  • Registered with a social security scheme or an eligible dependant
  • Agree to and be able to carry out the treatment familiarisation process with their relative and to accompany them to the dedicated consultation

Exclusion Criteria:

  • majors : Participants requiring urgent medical care that prevents them from completing an 8-week familiarisation period with the treatment

    • Participants at high risk of epileptic seizures, or with uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
    • Individuals with visual impairments that make the use of VR impossible
    • Individuals who refuse to wear the VR headset, in the investigator's judgement
    • Pregnant or breastfeeding women
    • Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
    • Individuals in an emergency situation who are unable to give their prior consent.

minors : Individuals requiring urgent care that prevents them from completing an 8-week acclimatisation period

  • Refusal expressed by the child, notwithstanding the prior consent of the parents or holders of parental authority
  • Children subject to a court-ordered protection measure involving a specific placement, which is incompatible with participation in the study
  • A person presenting a major risk of epileptic seizures, or uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
  • A person with visual impairments that make the use of VR impossible
  • A person refusing to wear the VR headset, in the investigator's judgement
  • Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
  • Individuals in an emergency situation who are unable to give their prior consent.

Caregiver: Vulnerable individuals referred to in Articles L. 1121-5 to 8 and L. 1122-1-2 of the Public Health Code are excluded from the study:

  • Pregnant women, women in labour or breastfeeding women
  • Persons deprived of their liberty by a judicial decision (including guardianship, curatorship and judicial protection) or an administrative decision
  • Persons receiving psychiatric care or admitted to a health or social care facility for purposes other than research
  • Persons in an emergency situation who are unable to give their prior consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Traditional treatment habituation method only

For each group, once they have been briefed, the following materials will be provided:

  • A monitoring kit and a logbook to support the user and monitor their adaptation to the treatment;
  • An information leaflet entitled 'Adapting to conventional treatment';
  • A dummy wristband designed to help the user get used to wearing the 'Embrace Plus' wristband, which measures the level of anxiety.

A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures.

This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS_VR).

The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention.

A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters.

Eksperimentel: Traditional care habituation combined with virtual reality

In addition to the traditional care habituation materials provided to participants in the control group, participants in this group will also receive:

  • A PREPASOINS_VR immersive virtual reality familiarisation kit to prepare participants for upcoming medical and care procedures through immersive 360° videos;
  • An information leaflet explaining how to use the virtual reality familiarisation kit.

The virtual reality programme includes eight care scenarios covering dental care, dental mobile unit visits, gynaecological and ophthalmological consultations, follow-up appointments for physical medicine and rehabilitation, somatic assessments, blood tests and electrocardiograms.

A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures.

This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS_VR).

The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention.

A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters.

An immersive virtual reality headset used with the PREPASOINS_VR solution. The device enables participants to view immersive 360-degree videos presenting different medical and care scenarios as part of the care familiarisation programme. It is used exclusively in the experimental group.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Skin Conductance (SC) During the Actual Treatment Procedure (µS)
Tidsramme: At Visit 1, during the actual treatment procedure (2-3 months after enrolment).

Skin conductance (SC), expressed in microsiemens (µS), measured using an Empatica wristband during the actual treatment procedure at Visit 1. Skin conductance reflects changes in the electrical conductance of the skin associated with sweat secretion by the eccrine sweat glands, particularly those located on the palms and soles. Skin conductance is a physiological measure of electrodermal activity (EDA) associated with sympathetic nervous system activity.

At Visit 1, during the actual treatment procedure (2-3 months after enrolment).

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Caregiver-Reported Patient Anxiety Score on the Visual Analogue Scale at 2-3 Months
Tidsramme: At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).

Patient anxiety score as perceived and reported by the caregiver, measured using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no anxiety and 10 indicates maximum anxiety. The assessment is performed at inclusion (baseline) and at Visit 1 (2-3 months after enrolment). The change in anxiety score between baseline and Visit 1 will be reported. Higher scores indicate higher levels of perceived anxiety (worse outcome).

At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).
Percentage of Care Provided During the Actual Treatment Procedure (%)
Tidsramme: Visit 1, during the actual treatment procedure (2-3 months after enrolment).

The degree of care provision during the actual treatment procedure, assessed by the healthcare professional using a numerical scale ranging from 0% (care not provided) to 100% (care fully provided). Intermediate values indicate partial care provision. A derived categorical variable will also be reported, distinguishing complete care provision (100%) from incomplete care provision (partial care provision or no care provided).

Visit 1, during the actual treatment procedure (2-3 months after enrolment).
Use of Premedication Before the Treatment Procedure (Yes/No)
Tidsramme: At Visit 1 (between 2 and 3 months after enrolment).

Use of premedication before the actual treatment procedure, recorded as a binary variable (yes/no). When premedication is used, its type (pharmacological or non-pharmacological) will also be recorded. For pharmacological premedication, the medication name and dose will be documented, when applicable.

At Visit 1 (between 2 and 3 months after enrolment).
Use and Acceptance of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA)
Tidsramme: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).

Use of conscious sedation with nitrous oxide/oxygen (MEOPA) during the actual treatment procedure, recorded as a categorical variable: administered and accepted, refused, or not used.

During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Duration of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA) (Minutes)
Tidsramme: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).

Duration of MEOPA administration during the actual treatment procedure, measured in minutes among participants who receive conscious sedation.

During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Number of Preparatory Visits Before the Actual Treatment Procedure
Tidsramme: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).

Number of preparatory visits ("dry runs") completed before the actual treatment procedure. A preparatory visit is defined as a visit during which the patient attends the treatment setting but the planned treatment is not performed. The total number of preparatory visits completed before the actual treatment will be recorded.

From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Pain Score During the Treatment Procedure Measured Using the Postoperative Pain Assessment Grid for Individuals with Intellectual Disabilities (GED-DI)
Tidsramme: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)

Pain experienced by the patient during the treatment procedure, measured using the Postoperative Version of the Pain Assessment Grid for Individuals with Intellectual Disabilities (Grille d'Évaluation de la Douleur - Déficience Intellectuelle, GED-DI). The scale consists of 27 behavioral items, each scored from 0 to 3, resulting in a total score ranging from 0 to 81. The scale is completed after the treatment by the healthcare professional who performed the procedure, with the assistance of a companion when necessary. Higher scores indicate greater pain intensity (worse outcome). Scores of 6-10 indicate mild pain, while scores of 11 or higher indicate moderate to severe pain.

Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)
Caregiver Satisfaction With the Care Provided During the Treatment Procedure
Tidsramme: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).

Caregiver satisfaction with the care provided during the actual treatment procedure, assessed using a 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater satisfaction and a better outcome. The questionnaire is completed by the caregiver, if present during the consultation.

Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Healthcare Professional-Rated Ease of Performing the Treatment Procedure
Tidsramme: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).

The perceived ease of performing the actual treatment procedure, assessed by the healthcare professional using a 5-point Likert scale ranging from 1 (very difficult) to 5 (very easy). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater ease of performing the procedure and a better outcome.

Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Duration of the Treatment Habituation Period (Days)
Tidsramme: From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).

Duration of the treatment habituation period, measured in days from the date of the first habituation session to the date of the actual treatment procedure. The duration is calculated as the number of calendar days between these two dates.

From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Number of Treatment Habituation Sessions
Tidsramme: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).

Total number of habituation sessions completed by each participant between enrolment and the actual treatment procedure.

From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
Recruitment Rate (%)
Tidsramme: From the start of recruitment until the end of the recruitment period, up to 12 months

Proportion of eligible participants who agreed to participate and were enrolled in the study, calculated as the number of enrolled participants divided by the number of eligible participants approached, multiplied by 100.

From the start of recruitment until the end of the recruitment period, up to 12 months
Recruitment Speed (Participants per Month)
Tidsramme: Up to 12 months

Average number of participants enrolled per month during the recruitment period, calculated as the total number of enrolled participants divided by the number of months of active recruitment.

Up to 12 months
Eligibility Rate (%)
Tidsramme: Up to 12 months

Proportion of individuals assessed for eligibility who met all study eligibility criteria, calculated as the number of eligible individuals divided by the total number of individuals assessed for eligibility, multiplied by 100.

Up to 12 months
participant Refusal Rate (%)
Tidsramme: Up to 12 months

Proportion of individuals approached for study participation who declined to participate, calculated as the number of individuals who refused participation divided by the total number of individuals approached, multiplied by 100.

Up to 12 months
Intervention Adherence Rate (%)
Tidsramme: From enrolment up to Visit 1, up to 3 months

Proportion of enrolled participants who completed at least two treatment habituation sessions, calculated as the number of participants completing at least two sessions divided by the total number of enrolled participants, multiplied by 100.

From enrolment up to Visit 1, up to 3 months
Acceptance Rate of the Dummy Wristband (%)
Tidsramme: During the habituation period prior to Visit 1, up to 3 months post-enrolment

Proportion of participants who accepted wearing the dummy wristband, calculated as the number of participants who accepted wearing the dummy wristband divided by the total number of participants offered the dummy wristband, multiplied by 100.

During the habituation period prior to Visit 1, up to 3 months post-enrolment
Acceptance Rate of the Embrace Plus Wristband on the Treatment Day (%)
Tidsramme: At Visit 1, up to 3 months post-enrolment

Proportion of participants who accepted wearing the Embrace Plus wristband during the actual treatment procedure, calculated as the number of participants who accepted wearing the wristband divided by the total number of participants offered the wristband, multiplied by 100.

At Visit 1, up to 3 months post-enrolment
Main Reasons for Non-Participation
Tidsramme: Up to 12 months

Main reasons reported by individuals who declined participation in the study, recorded as categorical data.

Up to 12 months
Time Interval Between Initial Contact and Study Inclusion (Days)
Tidsramme: From initial contact until study inclusion, up to 12 months

Time interval, measured in calendar days, between the date of initial contact with the potential participant and the date of study inclusion.

From initial contact until study inclusion, up to 12 months
Participant Follow-up Completion Rate (%)
Tidsramme: From enrolment until Visit 1 (2-3 months after enrolment).

Proportion of enrolled participants who completed the planned study follow-up assessment at Visit 1, calculated as the number of participants completing Visit 1 divided by the total number of enrolled participants, multiplied by 100

From enrolment until Visit 1 (2-3 months after enrolment).

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

30. marts 2028

Studieafslutning (Anslået)

30. marts 2028

Datoer for studieregistrering

Først indsendt

20. oktober 2026

Først indsendt, der opfyldte QC-kriterier

17. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026-A01473-48

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner